441 research outputs found
Contribution à l'étude du rôle du PACAP et du VIP dans le cerveau ainsi que dans des tumeurs d'origine neuroectodermique et hypophysaire
No full textDoctorat en sciences médicalesinfo:eu-repo/semantics/nonPublishe
Contribution à l'étude des domaines fonctionnels des récepteurs du VIP
No full textDoctorat en sciences médicalesinfo:eu-repo/semantics/nonPublishe
Contribution à l'étude des petites GTPases de la superfamille Ras dans les cellules pancréatiques
No full textDoctorat en sciences médicalesinfo:eu-repo/semantics/nonPublishe
Contribution à l'étude moléculaire et pharmacologique des récepteurs du VIP, de l'hélodermine et des PACAP
No full textDoctorat en sciences médicalesinfo:eu-repo/semantics/nonPublishe
Pituitary Adenylate Cyclase-Activating Polypeptide: Development of Selective Ligands for Pac1, Vpac1 and Vpac2 Receptors
No full textAt the time of its isolation, purification and sequencing in 1970-1972 by Said and Mutt (Said and Mutt, 1972;Mutt and Said, 1974), VIP was the third identified member of a peptide group that included secretin (Mutt et al, 1970) and glucagon (Bromer et al, 1957). The family signature was a N-terminal histidylseryl sequence separated by three amino acid residues from a phenylalanylthreonyl sequence. Synthesis of secretin, VIP, glucagon and analogs as well as a careful study of their biological activities revealed that there was no, or only negligible, interference of glucagon with secretin and VIP mediated responses, nor of secretin and VIP with the glucagon response. It was also rapidly recognized that VIP and secretin shared common in vitro properties and that each peptide interacted with its cognate receptor and with the other receptors (Bataille et al, 1974; Robberecht et al, 1976). It was also established for the three peptides that the N-terminal sequence was necessary for the high affinity recognition of the receptor and for induction of the biological activity, and that the C-terminus was necessary for a high affinity recognition. It was thus not possible to shorten significantly the molecule without a loss of the biological properties or peptide potency. This was a major point for the rational design of agonists and antagonists as well as for the interest of industry. Binding studies of125I-labeled peptides characterized the receptors and for each peptide high and low affinity sites were described (Christophe et al, 1976; Laburthe et al, 1978; Prieto et al, 1979).info:eu-repo/semantics/publishe
LES RECEPTEURS MEMBRANAIRES DU PEPTIDE VASOACTIF DE L'INTESTIN (VIP): HORMONE ET NEUROTRANSMETTEUR
No full textSCOPUS: NotDefined.jinfo:eu-repo/semantics/publishe
Peptides hormonaux ou neurotransmetteurs présents dans le tube digestif
No full text1ère édition 1er tirage Année Académique 1979-19803è candi.info:eu-repo/semantics/published
Modulation by n-alkanols of rat cardiac adenylate cyclase activity
No full textSCOPUS: ar.jinfo:eu-repo/semantics/publishe
Inhibition by heparin and dextran sulfate of stimulated rat pancreatic adenylate cyclase
No full textSCOPUS: ar.jinfo:eu-repo/semantics/publishe
L'adaptation des hydrolases et la sécrétion exocirne du pancréas du rat
No full textDoctorat en sciences médicalesinfo:eu-repo/semantics/nonPublishe
- …
